Liabilities / Assets
88th percentile
Higher debt load relative to assets than 88% of similar nonprofits.
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
Liabilities / Assets
88th percentile
Higher debt load relative to assets than 88% of similar nonprofits.
Liabilities / Revenue
39th percentile
Higher debt load relative to revenue than 39% of similar nonprofits.
Net Margin
17th percentile
Higher net margin than 17% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
1st percentile
Faster asset growth than 1% of similar nonprofits.
Revenue Growth
Score unavailable
No earlier valid filing was available within the previous three public years.
Assets
Down$15,844
Down $62,451 (-80%) from 2010
Net Assets
Down$3,507
Down $74,682 (-96%) from 2010
Liabilities
Up$12,337
Up $12,231 (+11539%) from 2010
Revenue
$528,514
No earlier filing loaded for comparison.
Expenses
Up$603,196
Up $182,866 (+44%) from 2010
Net Income
-$74,682
No earlier filing loaded for comparison.
This 2011 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
The hhv-6 foundation is a non-profit entity founded to encourage scientific exchange between scientists and to provide pilot grants for promising scientific and clinical research.the first priority of the foundation is to provide information and reagents to investigators who are interested in studying hhv-6. We maintain a repository of reagents including monoclonal antibodies,cosmids, hybridomas, cell lines and viral lysates that are donated by investigators around the world, and we make these valuable research materials available to researchers free of charge. We arrangecollaborations between investigators, host conferences and coordinate initiatives among investigators to develop consensus on issues relating to hhv-6. We attend conferences in the field of neurology and stem cell transplants to provide investigators with information about hhv-6, and to encourage clinical research.another important priority for the foundation is to encourage efforts to find antiviral compounds that are
No mirrored PDF or thumbnail assets are attached yet.
Displayed year
2011 • Form 990Summary only. Only limited summary data is available for this year.